Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK2 | Q05397 | 5/20 | 0.43 |
| ▸ | SYK | P43405 | 4/20 | 0.43 |
| ▸ | ULK1 | O75385 | 6/20 | 0.42 |
| ▸ | BRD4 | O60885 | 2/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
| ▸ | EGFR | P00533 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.40 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12085464 | 0.82 | PTK2 (0.49) | PTK2SYKULK1PTK2B | |
| SCHEMBL13386895 | 0.79 | PTK2 (0.43) | PTK2SYKULK1BRD4JAK2 | |
| SCHEMBL3279901 | 0.79 | PKM (0.42) | PTK2SYKULK1PTK2B | |
| SCHEMBL12085367 | 0.78 | PAK4 (0.53) | PTK2SYKULK1PTK2B | |
| SCHEMBL31229866 | 0.78 | PTK2 (0.63) | PTK2 | |
| SCHEMBL3283442 | 0.78 | LRRK2 (0.55) | PTK2SYKBRD4JAK2CREBBP | |
| SCHEMBL12085314 | 0.76 | PTK2 (0.49) | PTK2SYKULK1PTK2B | |
| SCHEMBL31229649 | 0.71 | PTK2 (0.63) | PTK2 | |
| SCHEMBL3283548 | 0.70 | LRRK2 (0.57) | PTK2SYKBRD4JAK2CREBBP | |
| SCHEMBL12085404 | 0.70 | ULK1 (0.46) | PTK2ULK1PTK2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7705004-B2 | Protein kinase inhibitors | PORTOLA PHARMACEUTICALS, INC. (US) | 2010-04-27 | — | — | US | claimed |
| WO-2009026107-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | WO | claimed |
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | PORTOLA PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054425-A1 | PROTEIN KINASE INHIBITORS | SYK, JAK2, BTK | PTK2 196/4885SYK 1/4885ULK1 656/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.